Predictive biomarkers for ovarian cancer

1. A set of reagents to measure the levels of biomarkers in a specimen, wherein the biomarkers are selected from the group consisting of the following panels of biomarkers or measurable fragments thereof:

(a) CA125, Apo A1, HE4, and FSH;

(b) CA125, Apo A1, HE4, FSH, and IL-6;

(c) CA125, Apo A1, HE4, FSH, and EGFR;

(d) CA125, Apo A1, HE4, FSH, and CRP;

(e) CA125, Apo A1, HE4, FSH, and transferrin;

(f) CA125, Apo A1, HE4, FSH, and transthyretin;

(g) CA125, Apo A1, HE4, FSH, IL-6, and transferrin;

(h) CA125, Apo A1, HE4, FSH, EGFR, and transferrin;

(i) CA125, Apo A1, HE4, FSH, CRP, and transferrin;

(j) CA125, Apo A1, HE4, FSH, IL-6, and transthyretin;

(k) CA125, Apo A1, HE4, FSH, EGFR, and transthyretin;

(l) CA125, Apo A1, HE4, FSH, CRP, and transthyretin;

(m) CA125, Apo A1, Beta-2 Microglobulin, and FSH;

(n) CA125, Apo A1, Beta-2 Microglobulin, FSH, and IL-6;

(o) CA125, Apo A1, Beta-2 Microglobulin, FSH, and EGFR;

(p) CA125, Apo A1, Beta-2 Microglobulin, FSH, and CRP;

(q) CA125, Apo A1, transferrin, and FSH;

(r) CA125, Apo A1, transferrin, FSH, and IL-6;

(s) CA125, Apo A1, transferrin, FSH, and EGFR;

(t) CA125, Apo A1, transferrin, FSH, and CRP;

(u) CA125, Apo A1, transthyretin, and FSH;

(v) CA125, Apo A1, transthyretin, FSH, and IL-6;

(w) CA125, Apo A1, transthyretin, FSH, and EGFR;

(x) CA125, Apo A1, transthyretin, FSH, and CRP; and

(y) CA125, Apo A1, Beta-2 Microglobulin, transferrin, transthyretin, and FSH.

2. The set of reagents of claim 1 , wherein the reagents are binding molecules.

3. The set of reagents of claim 2 , wherein the binding molecules are antibodies.

4. A test kit comprising the set of reagents of claim 1 .

5. A multianalyte panel assay comprising the set of reagents of claim 1 .

6. A method to assess the therapeutic efficacy of a cancer treatment, comprising: comparing the biomarker profiles in specimens taken from a subject before and after the treatment or during the course of treatment with a set of reagents according to claim 1 , wherein a change in the biomarker profile over time toward a non-cancer profile or to a stable profile is interpreted as efficacy.

7. A method for determining whether a subject potentially is developing cancer, comprising: comparing the biomarker profiles in specimens taken from a subject at two or more points in time with a set of reagents according to claim 1 , wherein a change in the biomarker profile toward a cancer profile, is interpreted as a progression toward developing cancer.

8. A method of predicting the likelihood of cancer in a subject, comprising: detecting the levels of biomarkers in a specimen using the set of reagents of claim 1 , wherein a change in the levels of the biomarkers, as compared with a control group of patients who do not have cancer, is predictive of cancer in that subject.

9. The method of claim 8 , wherein the cancer is ovarian cancer.

10. The method of claim 9 , wherein a change in the relative levels of the biomarkers is determined.

11. The method of claim 9 , wherein the specimen is selected from the group consisting of blood, serum, plasma, lymph, cerebrospinal fluid, ascites, urine and tissue biopsy.

12. The method of claim 9 , wherein the ovarian cancer is selected from the group consisting of serous, endometrioid, mucinous, and clear cell cancer.

13. The method of claim 9 , wherein the prediction of ovarian cancer includes a stage selected from the group consisting of Stage IA, IB, IC, II, III and IV tumors.

14. The method of claim 9 , further comprising creating a report of the relative levels of the biomarkers.

15. The method of claim 14 , wherein the report includes the prediction as to the presence or absence of ovarian cancer in the subject or the stratified risk of ovarian cancer for the subject, optionally by stage of cancer.

16. The method of claim 9 , wherein the sample is taken from a subject selected from the group consisting of subjects who are symptomatic for ovarian cancer and subjects who are at high risk for ovarian cancer.

17. The method of claim 9 , wherein the method has a sensitivity of at least about 85 percent and a specificity of at least about 85 percent.

18. The method of claim 17 , wherein the sensitivity and specificity are determined for a population of women who are symptomatic for ovarian cancer and have ovarian cancer as compared with a control group of women who are symptomatic for ovarian cancer but who do not have ovarian cancer.

19. A set of antibodies fixed to a microsphere to measure the levels of biomarkers in a specimen, wherein the biomarkers are selected from the group consisting of the following panels of biomarkers or measurable fragments thereof:

(a) CA125, Apo A1, HE4, and FSH;

(b) CA125, Apo A1, HE4, FSH, and IL-6;

(c) CA125, Apo A1, HE4, FSH, and EGFR;

(d) CA125, Apo A1, HE4, FSH, and CRP;

(e) CA125, Apo A1, HE4, FSH, and transferrin;

(f) CA125, Apo A1, HE4, FSH, and transthyretin;

(g) CA125, Apo A1, HE4, FSH, IL-6, and transferrin;

(h) CA125, Apo A1, HE4, FSH, EGFR, and transferrin;

(i) CA125, Apo A1, HE4, FSH, CRP, and transferrin;

(j) CA125, Apo A1, HE4, FSH, IL-6, and transthyretin;

(k) CA125, Apo A1, HE4, FSH, EGFR, and transthyretin;

(l) CA125, Apo A1, HE4, FSH, CRP, and transthyretin;

(m) CA125, Apo A1, Beta-2 Microglobulin, and FSH;

(n) CA125, Apo A1, Beta-2 Microglobulin, FSH, and IL-6;

(o) CA125, Apo A1, Beta-2 Microglobulin, FSH, and EGFR;

(p) CA125, Apo A1, Beta-2 Microglobulin, FSH, and CRP;

(q) CA125, Apo A1, transferrin, and FSH;

(r) CA125, Apo A1, transferrin, FSH, and IL-6;

(s) CA125, Apo A1, transferrin, FSH, and EGFR;

(t) CA125, Apo A1, transferrin, FSH, and CRP;

(u) CA125, Apo A1, transthyretin, and FSH;

(v) CA125, Apo A1, transthyretin, FSH, and IL-6;

(w) CA125, Apo A1, transthyretin, FSH, and EGFR;

(x) CA125, Apo A1, transthyretin, FSH, and CRP; and

(y) CA125, Apo A1, Beta-2 Microglobulin, transferrin, transthyretin, and FSH.